Vaccinations in RA: Stay Healthy!

Vaccinations

Vaccinations are a critical component of RA clinical management, and their importance in preventing infection cannot be stressed enough. The majority of patients with RA are on immunosuppressive treatment, and a data driven approach to vaccinations in this high-risk population is essential.

Does Antioxidant Intake Protect Against the Development of Rheumatoid Arthritis or Lupus?

8-3-2010-pills

Antioxidants may protect tissues against damage, reduce systemic inflammation, and modulate antigen presentation by inflammatory cells.  However, no large-scale investigation on whether dietary and/or supplement intake of antioxidants is protective against the development of autoimmune rheumatic disease.  Here, Costenbader et al (American Journal of Epidemiology 2010; 172(2): 205) explore antioxidant intake and the risk of […]

Leflunomide and Pregnancy Outcomes Explored

5-24-2010-leflunomide

Leflunomide use during early pregnancy is associated with fetal malformations in animal studies and is classified as a pregnancy category X by the U.S. Food and Drug Administration.  However, little is known about pregnancy outcomes in humans exposed to leflunomide in early pregnancy, particularly in those who receive “wash-out” with cholestyramine (a drug sequestrant).   Here, […]

Targeting Interleukin-17 Studied in Rheumatoid Arthritis

04-29-2010-targeting

Recently, it has been recognized that a subset of T cells producing the cytokine IL-17 contribute to the pathogenesis of rheumatoid arthritis (RA).  Animal studies have suggested that blockade of IL-17 may reduce the inflammatory signs and symptoms of inflammatory arthritis and reduce bone erosion.  Here, Genovese et al report Phase I/II data for LY2439821, […]

Does Tuberculosis Risk Differ Among TNF Inhibitors?

3-28-2010

Reactivation of latent tuberculosis is a recognized risk of TNF inhibitor use.  While there has been circumstantial evidence of greater risk with the monoclonal antibody TNF inhibitors (e.g. infliximab and adalimumab) compared with decoy receptor TNF inhibitors (e.g. etanercept), there have been few direct comparisons.  Here, Dixon et al (Ann Rheum Dis 2010; 69: 522-528) […]